Jasper Therapeutics, Inc.

Jasper Therapeutics, Inc. (Nasdaq: JASN) is a clinical-stage biotechnology company focused on developing therapeutics that target mast cell-driven diseases. The company's lead product candidate, briquilimab, is a humanized monoclonal antibody designed to block stem cell factor from binding to the CD117 receptor on mast and stem cells, potentially leading to depletion of these cells throughout the body.

The company is advancing briquilimab through multiple clinical development programs. In chronic spontaneous urticaria, Jasper is conducting the Phase 1b/2a BEACON study evaluating multiple ascending doses in adult patients with moderate to severe disease. The Phase 1b/2a SPOTLIGHT study in chronic inducible urticaria is examining single doses in patients with cold urticaria or symptomatic dermographism. Additionally, the company initiated the Phase 1b ETESIAN study in allergic asthma as a proof-of-concept trial. An open-label extension study allows patients from the BEACON and SPOTLIGHT studies to continue treatment with briquilimab at a 180mg dose every eight weeks.

Clinical data to date has demonstrated rapid onset of efficacy, with clinical responses observed as early as one week post-dose and complete responses as early as week two. The company reports that briquilimab has been well-tolerated across studies, with KIT-related adverse events generally being transient and low-grade. Jasper holds exclusive worldwide license agreements with Amgen for briquilimab development and commercialization across all indications and territories, as well as an exclusive license with Stanford University for the use of briquilimab in clearing diseased stem cells prior to hematopoietic stem cell transplantation.

The company's intellectual property portfolio includes in-licensed patents from both Amgen and Stanford, with issued U.S. and European patents expected to expire in 2027 absent patent term extensions. Jasper also owns multiple patent families directed to compositions and methods for treating mast cell-driven diseases, with expected expiration dates ranging from 2042 to 2046. The company operates as a smaller reporting company and is classified as a non-accelerated filer. More information is available at www.jaspertherapeutics.com.